Sign In
Buy GSK
$50.67
-1.48 (-2.84%)
At Close: Jun 18, 2026
New Strong Sell Stocks for January 23rd
06:40am, Thursday, 23'rd Jan 2025
ARCO, CAG and GSK have been added to the Zacks Rank #5 (Strong Sell) List on January 23, 2025.
Healthy Returns: Biotech and pharma M&A is off to a good start in 2025 — but will it last?
02:35pm, Tuesday, 21'st Jan 2025
Biotech and pharma dealmaking is off to a good start in 2025. Meanwhile, digital health fundraising defined by “David and Goliath dynamic” in 2024, report says.
GSK's Jemperli Gets EU Nod for Expanded Use in Endometrial Cancer
10:36am, Tuesday, 21'st Jan 2025
The European Commission approves GSK's Jemperli plus chemotherapy to treat all adult patients with primary, advanced or recurrent endometrial cancer.
Spero Therapeutics: Undervalued Based On Just Tebipenem And GSK Deal
08:00am, Sunday, 19'th Jan 2025
Spero Therapeutics' tebipenem, an oral carbapenem for cUTIs, has high approval potential, supported by a successful phase 3 trial and a GSK licensing deal. The need for oral carbapenems is critical du
Hallucinations in AI: How GSK is addressing a critical problem in drug development
06:13pm, Tuesday, 14'th Jan 2025
Hallucinations are a persistent problem in healthcare. Here's how GSK is using test-time compute scaling to improve its gen AI systems.
JNJ, GSK, LLY Announce M&A Deals at JP Morgan Conference
04:00pm, Tuesday, 14'th Jan 2025
J&J announces a big deal to acquire neuroscience company ITCI for $14.6 billion, while Lilly and GSK announce smaller deals.
GSK plc (GSK) 43rd Annual J.P. Morgan Healthcare Conference (Transcript)
12:56pm, Tuesday, 14'th Jan 2025
GSK plc (NYSE:GSK ) 43rd Annual J.P. Morgan Healthcare Conference January 14, 2025 10:30 AM ET Company Participants Emma Walmsley - CEO Luke Miels - Chief Commercial Officer Tony Wood - Chief Scientif
Healthcare sector poised for rebound in 2025
08:00pm, Monday, 13'th Jan 2025
The JPMorgan Healthcare Conference is a place where deals happen. As the conference kicked off, deals were announced from Eli Lilly (LLY), Johnson & Johnson (JNJ), and GSK (GSK).
Top 5 Cancer Pharma Stocks With Strong Risk/Reward In 2025
06:10pm, Monday, 13'th Jan 2025
This article will provide an in-depth analysis of drugs being developed to combat cancer. Big Pharma is keenly interested in the global cancer therapeutics market, which is expected to exceed $400 bil
GSK CEO on acquisition of biotech firm IDRx
12:39pm, Monday, 13'th Jan 2025
Emma Walmsley, GSK CEO, joins 'Money Movers' to discuss the company's deal to acquire IDRx, the impact of Robert F. Kennedy Jr.'s administration position, and much more.
Drugmakers rush to sign deals on first day of industry conference
12:07pm, Monday, 13'th Jan 2025
Drugmakers signed deals worth at least $18 billion in combined value on Monday, the first day of the healthcare industry's top conference in San Francisco.
GSK swoops for US cancer specialist in $1.15bn deal
03:23am, Monday, 13'th Jan 2025
GSK PLC (LSE:GSK, NYSE:GSK) has announced plans to acquire the US biotech company IDRx for up to $1.15bn, including $1bn upfront, in a bid to expand its portfolio of cancer therapies. The deal includ
GSK to buy US biotech firm IDRx for up to $1.15 billion
02:10am, Monday, 13'th Jan 2025
British drugmaker GSK said on Monday that it would pay up to $1.15 billion to buy Boston-based biopharmaceutical firm IDRx, which is developing a treatment for a rare type of tumour.
GSK Enters Agreement to Acquire IDRx, Inc.
02:05am, Monday, 13'th Jan 2025
PLYMOUTH, Mass.--(BUSINESS WIRE)--GSK plc (LSE/NYSE: GSK) and IDRx, Inc. (IDRx) today announced that they have entered into an agreement under which GSK will acquire IDRx, a Boston-based, clinical-sta
GSK's new shingles jab submitted for review by US regulator
03:40am, Friday, 10'th Jan 2025
GSK PLC (LSE:GSK, NYSE:GSK) has announced that the US Food and Drug Administration (FDA) is reviewing its new prefilled syringe version of Shingrix, its shingles vaccine. If approved, the updated del
